Lepu Biopharma Co. Ltd. Class H 2157

A late-stage gastric-cancer study met its overall-survival goal, supporting AstraZeneca's multibillion-dollar peak-sales estimate.

Lepu Biopharma (SEHK:2157) stock has shown mixed recent performance, with a gain over the past month but a decline over the past 3 months and the past year, prompting closer investor attention. See our latest analysis for Lepu Biopharma. The recent 7 day share price return of 10.54% contrasts with a 90 day share price decline of 27.85% and a 1 year total shareholder return decline of 17.62%, suggesting momentum has picked up in the short term after a weaker period. If you are comparing Lepu...

On November 20, 2025, BioDlink (Stock Code: 1875.HK), a leading biologics CDMO, together with Lepu Biopharma (2157.HK), announced the successful market launch of MEIYOUHENG®(Becotatug Vedotin injection) , the world's first EGFR-targeting antibody-drug conjugate (ADC). The launch also represents the first ADC fully manufactured by a CDMO to reach the market in China, underscoring a new level of maturity for the region's biopharmaceutical ecosystem.

BioDlink (1875.HK) congratulates its partner Lepu Biopharma (2157.HK) on receiving conditional marketing approval from China's National Medical Products Administration (NMPA) for MEIYOUHENG (Becotatug Vedotin injection). This Class 1 innovative antibody-drug conjugate (ADC) targets the epidermal growth factor receptor (EGFR) for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). Significantly, this is the world's first approved non-photoimmunological EGFR-targeted ADC a